Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2025 $ 268.09 millions
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2024 $ 167.13 millions
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2023 $ 131.31 millions
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2022 $ 196.25 millions
Ligand Pharmaceuticals Incorporated's Revenue in the fiscal year 2021 $ 277.13 millions
LGND Revenue second quarter 2026 Y/Y Growth Comment
Ligand Pharmaceuticals Incorporated achieved in the second quarter 2026, above Company average Revenue growth of 33.72% year on year, to $ 63.69 millions.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Revenue growth. While Ligand Pharmaceuticals Incorporated' s Revenue rise of 33.72% ranks overall at the positon no. 1560 in the second quarter 2026.
LGND Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
40 %
51.67 %
3.88 %
3rd Quarter
September
-
122.85 %
57.62 %
-50.26 %
2nd Quarter
June
33.72 %
14.69 %
57.49 %
-54.08 %
1st Quarter
March
14.1 %
45.43 %
-29.13 %
-3.74 %
FY
-
60.41 %
27.27 %
-
Financial Statements
Ligand Pharmaceuticals Incorporated's second quarter 2026 Revenue
Ligand Pharmaceuticals Incorporated achieved in the II. Quarter 2026 above company average sequential Revenue jump of 23.15%, to $ 63.69 millions, from $51.72 millions in the first quarter. LGND is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Ligand Pharmaceuticals Incorporated's Revenue growth quarter on quarter, overall rank is 474.
Ligand Pharmaceuticals Incorporated achieved in the II. Quarter 2026 above company average sequential Revenue jump of 23.15%, to $ 63.69 millions, from $51.72 millions in the first quarter. LGND is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Ligand Pharmaceuticals Incorporated's Revenue growth quarter on quarter, overall rank is 474.
Ligand Pharmaceuticals Incorporated's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 290.54
$ 274.48
$ 268.09
$ 251.04
$ 187.39
Y / Y Revenue Growth (TTM)
55.05 %
51.4 %
60.4 %
64.49 %
40.18 %
Year on Year Revenue Growth Overall
Ranking
# 287
# 380
# 255
# 2475
# 2150
Seqeuential Revenue Change (TTM)
5.85 %
2.38 %
6.79 %
33.97 %
3.36 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1560
# 1409
# 1160
# 235
# 2227
Cumulative Revenue growth Comment
Ligand Pharmaceuticals Incorporated saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 55.05% year on year, to $ 291 millions if the fiscal year would have ended in Jun 30 2026. Ligand Pharmaceuticals Incorporated's trailing twelve months Revenue growth was higher than company's average 24.07% and higher than 51.4% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 5.85 % from $274.48 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at24.07%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 5.85 % increase from $274.48 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 82 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 287, from total ranking in previous quarter at 380.
Ligand Pharmaceuticals Incorporated saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 55.05% year on year, to $ 291 millions if the fiscal year would have ended in Jun 30 2026. Ligand Pharmaceuticals Incorporated's trailing twelve months Revenue growth was higher than company's average 24.07% and higher than 51.4% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 5.85 % from $274.48 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at24.07%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 5.85 % increase from $274.48 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 82 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 287, from total ranking in previous quarter at 380.
About Ligand Pharmaceuticals Incorporated Revenue Growth Rates (LGND), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
58.55%